Checkpoint Inhibitor Nabs FDA Approval for Alveolar Soft Part Sarcoma

(MedPage Today) -- The FDA has approved atezolizumab (Tecentriq) for the treatment of alveolar soft part sarcoma (ASPS), the agency announced on Friday.
Atezolizumab, a PD-L1 immune checkpoint inhibitor already approved in lung cancers and other...